港股異動 | 奧思集團(1161.HK)漲10% 股價續創新高
格隆匯6月1日丨昨日大漲33%的奧思集團(1161.HK)今日繼續走強,現報1.64港元續創新高,漲幅10.07%,最新總市值11.16億港元。公司5月28日公吿稱,截至2021年3月31日止6個月公司收益3.15億港元,同比下跌14%;期內溢利為5880萬港元,上升34.1%。公吿指,未來六個月將有兩間新門市即將開幕,包括一間位於九龍塘又一城購物中心、佔地6,000平方呎的新Glycel Skinspa及奧思醫學美容中心旗艦店,取代現時1,600平方呎的Glycel Skinspa,以及一間位於將軍澳中心的新水磨坊美容中心,與同一個購物中心的現有Glycel門市相輔相成。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.